You are not authorized to access this page.
Search Within

Saad Zafar Usmani

Formats
  1. Meeting Abstract (223)
  2. Journal Article (82)
  3. Review (16)
  4. Research Letter (11)
  5. Correspondence (5)
  6. Editorial (4)
  7. Guidelines (3)
  8. Book Section (1)
Groups
  1. Hematologic Malignancies, Division of (171)
  2. Department of Medicine (168)
  3. Center for Hematologic Malignancies (161)
  4. Graduate Medical Education (151)
  5. Myeloma (149)
  6. GME, Medicine (142)

More Groups

People
  1. Alexander Lesokhin (129)
  2. Kylee Maclachlan (127)
  3. Sham Mailankody (113)
  4. Urvi Shah (110)
  5. Carlyn Rose Tan (105)
  6. Neha Korde (103)

More People

Years
  1. 2025 (42)
  2. 2024 (97)
  3. 2023 (123)
  4. 2022 (83)
Publications
  1. Blood (110)
  2. Clinical Lymphoma, Myeloma and Leukemia (81)
  3. Journal of Clinical Oncology (32)
  4. Blood Cancer Journal (16)
  5. Blood Advances (15)
  6. British Journal of Haematology (8)

More Publications

Publishers
  1. American Society of Hematology (125)
  2. Elsevier Inc. (94)
  3. American Society of Clinical Oncology (32)
  4. Nature Publishing Group (24)
  5. Elsevier Science, Inc. (10)
  6. John Wiley & Sons (9)

More Publishers

Results (345)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Sustained improvement in health-related quality of life in transplant-ineligible newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, and dexamethasone: MAIA final analysis of patient-reported outcomes
    Journal Article

    Perrot, A.; Facon, T.; Plesner, T.; Usmani, S. Z.; Kumar, S.; Bahlis, N. J.; Hulin, C.; Orlowski, R. Z.; Nahi, H.; Mollee, P.; more...
    European Journal of Haematology (2025)

    Fulltext@MSK | Save
  • Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group Study
    Journal Article

    Tan, C. R.; Asoori, S.; Huang, C. Y.; Brunaldi, L.; Popat, R.; Kastritis, E.; Martinez-Lopez, J.; Bansal, R.; Silva Corraes, A. D. M.; Chhabra, S.; more...
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • Outcomes of older adults and frail patients receiving idecabtagene vicleucel: A CIBMTR study
    Research Letter

    Akhtar, O. S.; Oloyede, T.; Brazauskas, R.; Afrough, A.; Hashmi, H.; Sidana, S.; Ahmed, N.; Bye, M.; Hansen, D.; Ferreri, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Daratumumab plus lenalidomide/dexamethasone in untreated multiple myeloma: Analysis of key subgroups of the MAIA study
    Journal Article

    Moreau, P.; Facon, T.; Usmani, S. Z.; Bahlis, N.; Raje, N.; Plesner, T.; Orlowski, R. Z.; Basu, S.; Nahi, H.; Hulin, C.; more...
    Leukemia (2025)

    Fulltext@MSK | Save
  • High WEE1 expression is independently linked to poor survival in multiple myeloma
    Journal Article

    Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Avutu, V.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
    Blood Cancer Journal (2025)

    Fulltext@MSK | Save
  • CD4+ T-cell lymphoma harboring a chimeric antigen receptor integration in TP53
    Journal Article

    Perica, K.; Jain, N.; Scordo, M.; Patel, R.; Eren, O. C.; Patel, U.; Gundem, G.; Domenico, D.; Mitra, S.; Socci, N. D.; more...
    New England Journal of Medicine (2025)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted chimeric antigen receptor T-cell therapy for multiple myeloma: An updated analysis
    Journal Article

    Jurgens, E. M.; Firestone, R. S.; Chaudhari, J.; Hosszu, K.; Devlin, S. M.; Shah, U. A.; Landa, J.; McAvoy, D. P.; Lesokhin, A. M.; Korde, N.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Evaluating serum free light chain ratio as a biomarker in multiple myeloma
    Journal Article

    Akhlaghi, T.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A. M.; Hassoun, H.; Lu, S. X.; Patel, D.; Shah, U. A.; Tan, C. R.; more...
    Haematologica (2025)

    Fulltext@MSK | Save
  • MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
    Journal Article

    Bhutani, M.; Robinson, M.; Foureau, D.; Atrash, S.; Paul, B.; Guo, F.; Grayson, J. M.; Ivanina-Foureau, A.; Pineda-Roman, M.; Varga, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma
    Review

    Voorhees, P. M.; Sborov, D. W.; Laubach, J.; Kaufman, J. L.; Reeves, B.; Rodriguez, C.; Silbermann, R.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; more...
    Future Oncology (2025)

    Fulltext@MSK | Save